People · Operator
Named in public records as an officer, director or promoter · active 2010–2013 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sancilio & Company, Inc. | — | Pharmaceuticals | Series B | $22.3M | $680.1M | 2012 |
| Protea Biosciences Group, Inc. | — | Biotechnology | Series A | $16.6M | $22.8M | 2010 |
| Protea Biosciences Inc | — | Biotechnology | Series A | $8.7M | $38.0M | 2011 |
Roderick Jackson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Roderick Jackson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Turner | 2 | 6 |
| Scott Segal | 2 | 5 |
| Steve Antoline | 2 | 2 |
| Stanley Hostler | 2 | 2 |
| Ed Roberson | 2 | 2 |
| Daniel Flynn | 2 | 2 |
| Patrick Gallagher | 1 | 11 |
| Patrick Gray | 1 | 10 |
| Dennis Langer | 1 | 9 |
| Leonard Harris | 1 | 7 |
| Tom Clark | 1 | 4 |
| Frederick Sancilio | 1 | 4 |
| Maged Shenouda | 1 | 3 |
| JOHAN (THIJS) M. SPOOR | 1 | 3 |
| Leonard P Harris | 1 | 3 |
| Thomas Clark | 1 | 3 |
| Alan Dunton | 1 | 2 |
| Matthew Powell | 1 | 2 |
| Daniel M. Flynn | 1 | 2 |
| Andrew Folmer | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.